390 research outputs found
A Picture from a National Reference Center for Molecular Pathology
Introduction: The Portuguese healthcare system had to adapt at short notice to the COVID-19 pandemic. We implemented workflow changes to our molecular pathology laboratory, a national reference center, to maximize safety and productivity. We assess the impact this situation had on our caseload and what conclusions can be drawn about the wider impact of the pandemic in oncological therapy in Portugal. Material and Methods. We reviewed our database for all oncological molecular tests requested between March and April of 2019 and 2020. For each case, we recorded age, sex, region of the country, requesting institution, sample type, testing method, and turnaround time (TAT). A comparison between years was made. Results: The total number of tests decreased from 421 in 2019 to 319 in 2020 (p = 0.0027). The greatest reduction was in clinical trial-related cases. Routine cases were similar between years (267 vs. 256). TAT was higher in 2019 (mean 15 days vs. 12.3 days; p = 0.0003). Medium- to large-sized public hospitals in the north of the country were mostly responsible for the reduction in cases (p = 0.0153). Conclusions: Case reduction was observed at hospitals that have mostly been involved in the treatment of COVID-19 and in the north of the country, the region worst-hit by the pandemic. Similar to other studies, our TAT decreased, even with a similar number of routine cases. Thus, we conclude that it is possible to successfully adapt the workflow of a molecular pathology laboratory to new safety standards without losing efficiency.publishersversionpublishe
Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).
Objective: The somatic point mutation in the BRAF gene, which results in a valine-to-glutamate sub-
stitution at residue 600 (BRAF
V600E
), is an ideal hallmark of papillary thyroid carcinoma (PTC). How-
ever, its prevalence is varyingly reported in different studies, and its expression in the follicular variant
PTC is controversial, reducing its potential usefulness as diagnostic marker.
Design and methods: We developed an assay based on mutant allele-specific PCR amplification (MASA)
to detect BRAF mutation. We compared the sensitivity of MASA, single-strand conformation poly-
morphism (SSCP) and direct DNA sequencing of PCR products. Then, we used MASA 78 to analyze
78 archival thyroid tissues, including normal samples, follicular adenomas, follicular carcinomas and
PTC.
Results: The MASA assay proved to be a more sensitive method than SSCP and DNA sequencing of
PCR products. BRAF mutation was found by MASA in 19/43 (44.2%) of PTC, including 14/31
(45.2%) classic forms and 5/12 (41.7%) follicular variants. No mutations of BRAF were detected
in the normal thyroid tissues, nor in follicular adenomas or follicular carcinomas. No correlation
was found between BRAF mutation and clinicopathologic features nor with recurrence during a post-
operative follow-up period of 4–11 years. BRAF
V600E
significantly correlated with absence of node
metastasis.
Conclusions: BRAF
V600E
is present in PTC, both in the classic form and in follicular variant with simi-
lar prevalence. No correlation was found between BRAF mutation and aggressive clinical behavior.
MASA-PCR proved to be a specific, sensitive and reliable method to detect BRAF T1799A in DNA
extracted from different sources, including cytologic samples obtained either fresh or from archival
glass slides. We propose this method as a useful tool to improve accuracy of preoperative diagnosis
identifying PTC from biopsies with indeterminate cytologic findings
Paleopathological Approach to the Study of a Christian Relic: The Case of the Blessed Maria Lorenza Longo
The Blessed Maria Lorenza Longo, founder of the hospital of Santa Maria del Popolo degli Incurabili and the Order of the Capuchin Poor Clares in Naples, Italy, died on 21 October 1539 and was recently beatified on 9 October 2021. The relic, a fully skeletonized cranium, underwent visual and radiological inspection. The biological profile supports the at¬tribution of female sex of the relic, whereas the age at death is estimated to be younger than that reported by historians. A paleopathological survey was conducted to evaluate the historical reports of poisoning or rheumatoid arthritis affecting Maria Longo. Given the limited skeletal data, it was not possible to confirm the presence of these claims. No obvious in¬dicators of dietary deficiencies were observed, and the tertiary syphilis hypothesized by textual sources was excluded. Postmortem alterations of the relic were clearly visible on the superior aspect of the cranium and testified to the worship of the relic
Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes.
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma
Controversies in the surgical management of thyroid follicular neoplasms. Retrospective analysis of 721 patients
n/
Correlation of NM23-H1 cytoplasmic expression with metastatic stage in human prostate cancer tissue
n/
A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer
The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease. The genetic alterations underlying this heterogeneity have been thoroughly characterized through omic approaches requiring elevated efforts and costs. In order to translate the knowledge of CRC molecular heterogeneity into a practical clinical approach, we utilized a simplified Next Generation Sequencing (NGS) based platform to screen a cohort of 77 patients treated with first-line conventional therapy. Samples were sequenced using a panel of hotspots and targeted regions of 22 genes commonly involved in CRC. This revealed 51 patients carrying actionable gene mutations, 22 of which carried druggable alterations. These mutations were frequently associated with additional genetic alterations. To take into account this molecular complexity and assisted by an unbiased bioinformatic analysis, we defined three subgroups of patients carrying distinct molecular patterns. We demonstrated these three molecular subgroups are associated with a different response to first-line conventional combination therapies. The best outcome was achieved in patients exclusively carrying mutations on TP53 and/or RAS genes. By contrast, in patients carrying mutations in any of the other genes, alone or associated with mutations of TP53/RAS, the expected response is much worse compared to patients with exclusive TP53/RAS mutations. Additionally, our data indicate that the standard approach has limited efficacy in patients without any mutations in the genes included in the panel. In conclusion, we identified a reliable and easy-to-use approach for a simplified molecular-based stratification of mCRC patients that predicts the efficacy of the first-line conventional combination therapy
Thyroid Cancer and Fibroblasts
Thyroid cancer is the most common type of endocrine cancer, and its prevalence continue to rise. Non-metastatic thyroid cancer patients are successfully treated. However, looking for new therapeutic strategies is of great importance for metastatic thyroid cancers that still lead to death. With respect to this, the tumor microenvironment (TME), which plays a key role in tumor progression, should be considered as a new promising therapeutic target to hamper thyroid cancer progression. Indeed, thyroid tumors consist of cancer cells and a heterogeneous and ever-changing niche, represented by the TME, which contributes to establishing most of the features of cancer cells. The TME consists of extracellular matrix (ECM) molecules, soluble factors, metabolites, blood and lymphatic tumor vessels and several stromal cell types that, by interacting with each other and with tumor cells, affect TME remodeling, cancer growth and progression. Among the thyroid TME components, cancer-associated fibroblasts (CAFs) have gained more attention in the last years. Indeed, recent important evidence showed that thyroid CAFs strongly sustain thyroid cancer growth and progression by producing soluble factors and ECM proteins, which, in turn, deeply affect thyroid cancer cell behavior and aggressiveness. Hence, in this article, we describe the thyroid TME, focusing on the desmoplastic stromal reaction, which is a powerful indicator of thyroid cancer progression and an invasive growth pattern. In addition, we discuss the origins and features of the thyroid CAFs, their influence on thyroid cancer growth and progression, their role in remodeling the ECM and their immune-modulating functions. We finally debate therapeutic perspectives targeting CAFs
2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Abstract Background The clinical impact of the positivity of the Deauville scale (DS) of positron emission tomography (PET) performed at the end of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in patients with advanced Hodgkin lymphoma (HL), in terms of providing rationale to shift poor responders onto a more intensive regimen, remain to be validated by histopathology. Patients and methods This prospective trial involved patients with stage IIB/IV HL who after six ABVD cycles underwent PET (PET6) and core-needle cutting biopsy (CNCB) of 2-deoxy-2[F-18] fluoro- d -glucose (FDG)-avid lymph nodes. Patients received high-dose chemotherapy/autologous haematopoietic stem cell rescue (HDCT/AHSCR) if CNCB was positive for HL, alternatively, if CNCB or PET was negative, received observation or consolidation radiotherapy (cRT) on residual nodal masses, as initially planned. The end-point was 5-year progression-free survival (PFS). Results In all, 43 of the 169 (25%) evaluable patients were PET6 positive (DS 4, 32; DS 5, 11). Among them, histology showed malignancy (HL) in 100% of DS 5 scores and in 12.5% of DS 4 scores. Fifteen patients with positive biopsy received HDCT/AHSCR, whereas 28 patients with negative biopsy, as well as 126 patients with negative PET6, continued the original plan (cRT, 78 patients; observation, 76 patients). The 5-year PFS in the negative PET6 group, negative biopsy group and positive biopsy group was 95.4%, 100% and 52.5%, respectively. Conclusion DS positivity of end-of-ABVD PET in advanced HL carried a certain number of CNCB-proven non-malignant FDG-uptakes. The DS 4 scores which were found to have negative histology appeared to benefit from continuing the original non-intensive therapeutic plane as indicated by the successful outcome in more than 95% of them by obtaining similar 5-year PFS to the PET6-negative group. By contrast, the DS 5 score had consistently positive histology and was associated with unsuccessful conventional therapy, promptly requiring treatment intensification or innovative therapeutic approaches
- …